Exploration of Drug Science

Table 1. Baseline characteristics of patients with and without prophylactic metoclopramide use.

Characteristic	Without metoclopramide (n = 45)	With metoclopramide (n = 199)	p-value
Age, years	70.91 ± 9.80	69.99 ± 9.30	0.120
BMI, kg/m²	20.08 ± 2.20	19.98 ± 1.69	0.140
Gender, n (%)
Female	21.0 (46.7)	85.0 (42.7)	0.800
Male	24.0 (53.3)	114.0 (57.3)	0.800
Cancer subtype, n (%)
Respiratory system	9.0 (20.0)	30.0 (15.1)	0.055
Digestive system	17.0 (37.8)	119.0 (59.8)
Urogenital system	12.0 (26.7)	33.0 (16.6)
Others	7.0 (15.6)	17.0 (8.5)
Stage, n (%)
I–III	13.0 (28.9)	40.0 (20.1)	0.300
IV	32.0 (71.1)	159.0 (79.9)	0.300
Underlying diseases, n (%)
0	13.0 (28.9)	81.0 (40.7)	0.200
1	32.0 (71.1)	118.0 (59.3)	0.200
Past history, n (%)
0	10.0 (22.2)	69.0 (34.7)	0.200
1	35.0 (77.8)	130.0 (65.3)	0.200

Return to article view

Data are presented as n (%) or mean ± SD. BMI: body mass index (measured in kilograms per square meter (kg/m²)); 0: no underlying disease; 1: presence of ≥ 1 chronic condition.

Supplementary materials

The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/1008148_sup_1.pdf.

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/1008148_sup_2.pdf.

Declarations

Acknowledgments

The authors would like to thank the clinical staff at the Qinghai University Affiliated Hospital for their support in data collection.

Author contributions

XM: Methodology, Data curation, Writing—original draft, Resources. YY: Methodology, Formal analysis, Writing—original draft, Writing—review & editing. LS: Formal analysis, Visualization. LZ: Investigation, Data curation. DR: Visualization. YL: Investigation. ZL: Investigation, Data curation, Writing—review & editing, Supervision, Resources. JZ: Conceptualization, Writing—review & editing, Supervision, Project administration, Funding acquisition. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

This retrospective study was approved by the Ethics Committee of Qinghai University Affiliated Hospital (Approval No. AF-RHEC-0018-01). The study complies with the Declaration of Helsinki.

Consent to participate

Informed consent was waived due to the retrospective nature of the study and the use of anonymized data.

Consent to publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy and ethical restrictions.

Funding

This study was supported by the Kunlun Talent and Plateau Famous Doctor Project of Qinghai Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Abdel Shaheed C, Hayes C, Maher CG, Ballantyne JC, Underwood M, McLachlan AJ, et al. Opioid analgesics for nociceptive cancer pain: A comprehensive review. CA Cancer J Clin. 2024;74:286–313. [DOI] [PubMed]

Chen D, Chen D, Sun H, You D, Tang H, Li S, et al. Efficacy of Multidisciplinary Pain Management for Advanced Cancer Patients. Pain Manag Nurs. 2025;26:349–57. [DOI] [PubMed]

Chapman EJ, Edwards Z, Boland JW, Maddocks M, Fettes L, Malia C, et al. Practice review: Evidence-based and effective management of pain in patients with advanced cancer. Palliat Med. 2020;34:444–53. [DOI] [PubMed]

DeForge SM, Smith K, Anderson KA, Baltazar AR, Beck M, Enzinger AC, et al. Pain coping, multidisciplinary care, and mHealth: Patients’ views on managing advanced cancer pain. Psychooncology. 2024;33:e6308. [DOI] [PubMed] [PMC]

Ji J, Guo J, Chi Y, Su F. Cancer Pain Management with Traditional Chinese Medicine: Current Status and Future Perspectives. Am J Chin Med. 2024;52:123–35. [DOI] [PubMed]

Sande TA, Laird BJA, Fallon MT. The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review. J Palliat Med. 2019;22:90–7. [DOI] [PubMed]

Mallick-Searle T, Fillman M. The pathophysiology, incidence, impact, and treatment of opioid-induced nausea and vomiting. J Am Assoc Nurse Pract. 2017;29:704–10. [DOI] [PubMed]

Varrassi G, Müller-Schwefe GHH. The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment? Curr Med Res Opin. 2012;28:823–31. [DOI] [PubMed]

Singhal Y, Pingoliya SK, Saji S, Gaurav RP. Comparison of Efficacy and Safety of Prophylactic Use of Metoclopramide and Haloperidol on Morphine-induced Nausea and Vomiting in Cancer Patients: A Comparative, Randomised, Prospective Study. Indian J Palliat Care. 2024;30:375–9. [DOI] [PubMed] [PMC]

10.

Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, et al. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Oncologist. 2018;23:367–74. [DOI] [PubMed] [PMC]

11.

Gottlieb M, Carlson JN, Peksa GD. Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting. Cochrane Database Syst Rev. 2022;5:CD013860. [DOI] [PubMed] [PMC]

12.

Choo KH, Manikam RA, Yoong KPY, Kandasamy VA. Prophylactic metoclopramide use in trauma patients given tramadol: A randomised, double-blinded, placebo-controlled trial. Hong Kong J Emerg Med. 2019;26:98–105. [DOI]

13.

Łysiak K, Łysiak A, Maziarz B, Przywara P, Bogumiłło N, Ściurka K, et al. Nausea and vomiting associated with chemotherapy and principles of management in their prevention. Prospects Pharm Sci. 2025;23:74–9. [DOI]

14.

Tamura T, Kawakado K, Makimoto GO, Nakanishi M, Kuyama S. Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study. In Vivo. 2021;35:1737–42. [DOI] [PubMed] [PMC]

15.

Simpson PM, Bendall JC, Middleton PM. Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials. Emerg Med Australas. 2011;23:452–7. [DOI] [PubMed]

16.

Battah MM, Zainal H, Ibrahim DA, Hanafiah NHBM, Syed Sulaiman SA, Halboup A. Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana’a, Yemen. Int J Gen Med. 2024;17:2077–90. [DOI] [PubMed] [PMC]

17.

Ai M, Cai Y, Zeng Y, Xiong D. Efficacy of acupoint injection of metoclopramide for post-chemotherapy vomiting: A systematic review and meta-analysis. Medicine (Baltimore). 2024;103:e37569. [DOI] [PubMed] [PMC]

18.

van der Vorst MJDL, Toffoli EC, Beusink M, van Linde ME, van Voorthuizen T, Brouwer S, et al. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. Oncologist. 2021;26:e173–81. [DOI] [PubMed] [PMC]

19.

Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr. 2020;43:49–56. [DOI] [PubMed] [PMC]

20.

Smith HS, Smith JM, Smith AR. An overview of nausea/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103–14. [DOI] [PubMed]

21.

Fallon R, Fraser C, Moriarty K. Recommended management of nausea and vomiting. Prescriber. 2007;18:50–61. [DOI]

22.

Culver MA, Richards EC, Jarrell DH, Edwards CJ. Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study. J Emerg Med. 2017;53:629–34. [DOI] [PubMed]

23.

Antiemetic drugs: pharmacology and an overview of their clinical use [Internet]. World Federation of Societies of Anaesthesiologists; c2026 [cited 2025 Oct 20]. Available from: https://resources.wfsahq.org/uia/volume-31/antiemetic-drugs-pharmacology-and-an-overview-of-their-clinical-use/

24.

Kalas MA, Trivedi B, Kalas M, Chavez LO, McCallum RW. Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile. Gastrointest Disord. 2023;5:317–28. [DOI]

25.

Quigley EMM. Prokinetics in the Management of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil. 2015;21:330–6. [DOI] [PubMed] [PMC]

26.

Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol. 2009;24:537–46. [DOI] [PubMed]

27.

Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol. 2014;722:67–78. [DOI] [PubMed]

28.

Coluzzi F, Pappagallo M; National Initiative on Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71:425–33. [PubMed]

29.

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313. [DOI] [PubMed]

30.

Portenoy RK, Farrar JT, Backonja MM, Cleeland CS, Yang K, Friedman M, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–99. [DOI] [PubMed]

31.

Corli O, Santucci C, Corsi N, Radrezza S, Galli F, Bosetti C. The Burden of Opioid Adverse Events and the Influence on Cancer Patients' Symptomatology. J Pain Symptom Manage. 2019;57:899–908.e6. [DOI] [PubMed]

32.

Vignaroli E, Bennett MI, Nekolaichuk C, De Lima L, Wenk R, Ripamonti CI, et al. Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. J Palliat Med. 2012;15:186–91. [DOI] [PubMed]